Immunogenicity to cerliponase alfa, an enzyme replacement therapy for patients with CLN2 disease: results from a phase 1/2 study

被引：0
|
作者：
Cherukuri, Anu [1 ]
Cahan, Heather [1 ]
Van Tuyl, Andrea [1 ]
de Hart, Greg [1 ]
Slasor, Peter [1 ]
Bray, Laurie [1 ]
Henshaw, Josh [1 ]
Ajayi, Temitayo [1 ]
Jacoby, Dave [1 ]
O'Neill, Charles [1 ]
Schweighardt, Becky [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期
关键词：
D O I：
10.1016/j.ymgme.2016.11.064
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
55
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [41] Serial brain MRI volumetrics and tractography of atypical CLN2 patients receiving ICV cerliponase alfa treatment
    Kao, Audrey
    Chang, Harriet
    Nestrasil, Igor
    Wang, Raymond Y.
    MOLECULAR GENETICS AND METABOLISM, 2025, 144 (02) : 60 - 61
  • [42] Cerliponase alfa for the treatment of CLN2 disease in an expanded patient cohort including children younger than three years: Interim results from an ongoing clinical study
    Schulz, Angela
    de los Reyes, Emily
    Specchio, Nicola
    Gissen, Paul
    Cahan, Heather
    Slasor, Peter
    Ajayi, Temitayo
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S145 - S145
  • [43] Cerliponase Alfa for the Treatment of CLN2 Disease in an Expanded Patient Cohort Including Children Younger than Three Years: Interim Results from an Ongoing Clinical Study
    Schulz, A.
    de los Reyes, E.
    Specchio, N.
    Gissen, P.
    Cahan, H.
    Slasor, P.
    Ajayi, T.
    ANNALS OF NEUROLOGY, 2019, 86 : S144 - S144
  • [44] 关于脑内灌注Cerliponase alfa治疗CLN2疾病的综述
    王丹
    孙婷婷
    孟雪莲
    陈长兰
    辽宁大学学报(自然科学版), 2019, 46 (03) : 237 - 243
  • [45] Intracerebrovascular enzyme replacement therapy for CLN2 disease: A collaborative, multi-disciplinary approach
    Pires-Barracosa, Naomi
    Movsesyan, Nina
    Truong, Nicole
    Olaya, Joffre
    See, Susan
    Adlard, Kathleen
    Stockton, Winifred
    Wang, Raymond
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S117 - S117
  • [46] Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study
    Schulz, Angela
    Specchio, Nicola
    Reyes, Emily de los
    Gissen, Paul
    Nickel, Miriam
    Trivisano, Marina
    Aylward, Shawn C.
    Chakrapani, Anupam
    Schwering, Christoph
    Wibbeler, Eva
    Westermann, Lena Marie
    Ballon, Douglas J.
    Dyke, Jonathan P.
    Cherukuri, Anu
    Bondade, Shailesh
    Slasor, Peter
    Pfeffer, Jessica Cohen
    LANCET NEUROLOGY, 2024, 23 (01): : 60 - 70
  • [47] A long-term observation of ophthalmology assessment in atypical CLN2 patients receiving ICV cerliponase alfa treatment
    Kao, Audrey
    Chang, Harriet
    Bhola, Rahul
    Wang, Raymond Y.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [48] Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)
    Gutic, Medo
    Milosavljevic, Milos N.
    Safiye, Teodora
    Milidrag, Ardea
    Jankovic, Slobodan M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (05) : 561 - 570
  • [49] Real-world clinical outcomes of intraventricular cerliponase alfa in CLN2 disease: 4.5-year update from an independent ongoing observational study
    Schulz, Angela
    Schwering, Christoph
    Wibbeler, Eva
    Westermann, Lena
    Dulz, Simon
    Lezius, Susanne
    Nickel, Miriam
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S109 - S109
  • [50] Intravitreal enzyme replacement therapy to prevent retinal disease progression in children with neuronal ceroid lipofuscinosis type 2 (CLN2): Unilateral injection results
    Rogers, David L.
    de los Reyes, Emily C.
    Mendel, Thomas A.
    Caprul, Brian J.
    Podlasiak, Sarah
    Jordan, Catherine O.
    MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
12345